US 11795216
Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
granted A61KA61K2039/54A61K39/3955
Quick answer
US patent 11795216 (Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics) held by Takeda Pharmaceutical Company Limited expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/54, A61K39/3955, A61P, A61P17/06